Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Blocking the ATP11B Gene Restores Ovarian Cancer Cell Sensitivity to Cisplatin

By BiotechDaily International staff writers
Posted on 02 May 2013
The expression of a protein in the cellular membrane of ovarian cancer cells was found to mediate the development of resistance to platinum-containing chemotherapeutic compounds while blocking this expression restored sensitivity to the drugs.

Platinum compounds, such as cisplatin and carboplatin, are first line therapeutics in the treatment of many solid tumors, as they induce DNA cross-linking that prevents DNA synthesis and repair in rapidly dividing cells. However, the cells frequently develop resistance mechanisms in the form of reduced platinum uptake or increased platinum export that limit the extent of DNA damage.

Using genomic analyses investigators at the University of Texas MD Anderson Cancer Center (Houston, USA) found that ATP11B gene expression was substantially increased in cisplatin-resistant cells. ATP11B is a P-type ATPase, which is phosphorylated in the intermediate state and drives uphill transport of ions across membranes.

The investigators reported in the April 15, 2013, online edition of the Journal of Clinical Investigation that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin resistance in human ovarian cancer cell lines. ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin in vitro. Combined therapy of cisplatin and ATP11B-targeted siRNA (short interfering RNA) significantly decreased cancer growth in mice bearing ovarian tumors derived from cisplatin-sensitive and -resistant cells.

In vitro mechanistic studies on cellular platinum content and cisplatin efflux kinetics indicated that ATP11B enhanced the export of cisplatin from cells.

The investigators concluded that, "These findings identify ATP11B as a potential target for overcoming cisplatin resistance."

Related Links:
University of Texas MD Anderson Cancer Center


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.